Journal Information
Vol. 60. Issue 9.
Pages 559-564 (September 2024)
Share
Share
Download PDF
More article options
Vol. 60. Issue 9.
Pages 559-564 (September 2024)
Original Article
Impact of OLD/Emphysema in LC Mortality Risk in Screening Programs: An Analysis of NLST and P-IELCAP
Visits
743
Jessica Gonzáleza,b,
Corresponding author
jgonzalezgutierrez88@gmail.com

Corresponding author.
, Luis M. Seijob,c, Juan P. de-Torresd,e, Iván D. Beníteza,b, María del Mar Ocónd, Ferran Barbéa,b, Juan P. Wisniveskyf, Javier J. Zuluetag
a Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
b CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain
c Pulmonary Department, Clínica Universidad de Navarra, Madrid, Spain
d Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain
e Navarra's Health Research Institute (IDISNA), Pamplona, Spain
f Divisions of General Internal Medicine and Pulmonary and Critical Care Medicine, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
g Pulmonary, Critical Care and Sleep Division, Mount Sinai Morningside Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (1)
Table 1. Sociodemographic and Clinical Characteristics According to Presence of OLD and/or Emphysema.
Additional material (1)
Abstract
Introduction

The impact of obstructive lung disease (OLD) and emphysema on lung cancer (LC) mortality in patients undergoing LC screening is controversial.

Methods

Patients with spirometry and LC diagnosed within the first three rounds of screening were selected from the National Lung Screening Trial (NLST) and from the Pamplona International Early Lung Cancer Detection Program (P-IELCAP). Medical and demographic data, tumor characteristics, comorbidities and presence of emphysema were collected. The effect of OLD and emphysema on the risk of overall survival was assessed using unadjusted and adjusted Cox models, competing risk regression analysis, and propensity score matching.

Results

Data from 353 patients with LC, including 291 with OLD and/or emphysema and 62 with neither, were analyzed. The median age was 67.3 years-old and 56.1% met OLD criteria, predominantly mild (1: 28.3%, 2: 65.2%). Emphysema was present in 69.4% of the patients. Patients with OLD and/or emphysema had worse survival on univariate analysis (HR: 1.40; 95% CI: 0.86–2.31; p=0.179). However, after adjusting for LC stage, age, and sex, the HR was 1.02 (95% CI: 0.61–1.70; p=0.952). Specific LC survival between both groups showed an adjusted HR of 0.90 (95% CI: 0.47–1.72; p=0.76). Propensity score matching found no statistically significant difference in overall survival (HR: 1.03; 95% CI: 0.59–1.9; p=0.929).

Conclusion

The survival of LC patients diagnosed in the context of screening is not negatively impacted by the coexistence of mild OLD and/or emphysema.

Keywords:
COPD
Emphysema
Lung cancer screening

Article

These are the options to access the full texts of the publication Archivos de Bronconeumología
Member
If you are a member of SEPAR:
  • Go to >>>SEPAR<<< website and sign in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de Bronconeumología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?